Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
Novartis AG · Now $145.68
+1.0% in 3d after detection
Post-detection moves
1h
—
1d
+0.0%
3d
+1.0%
7d
-0.2%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS